CGeneTech Hazardous Waste Pollution Prevention and Control Information Disclosure

Categories:Company News
Author:
Origin:
Time of issue:2023-08-19
Views:0

(Summary description)

CGeneTech Hazardous Waste Pollution Prevention and Control Information Disclosure

(Summary description)

Categories:Company News
Author:
Origin:
Time of issue:2023-08-19
Views:0

CGeneTech Hazardous Waste Pollution Prevention and Control Information Disclosure

According to the requirements of laws and regulations such as the Environmental Protection Law of the People's Republic of China, the Administrative Penalty Law of the People's Republic of China, and the Measures for Environmental Information Disclosure of Enterprises and Institutions, the information on the prevention and control of hazardous waste pollution in our unit is hereby disclosed as follows:

1、 Basic information

Unit Name: CGeneTech(Suzhou,China)Co.,Ltd

Unified Social Credit Code: 913205945502681671

Legal representative: Ding Juping

Registered address: Units 101 and 102, Building C11, Biopharmaceutical Industrial Park, No. 218 Xinghu Street, Industrial Park, Suzhou City, Jiangsu Province

Contact number: 0512-62956960

2、 Hazardous waste information

（1） Basic information:

Our company has a total of 4 laboratories, including the Synthesis Department Laboratory, Analysis Department Laboratory, Preparation Department Laboratory, and Biology Department Laboratory; Two hazardous waste storage points are set up in the synthesis laboratory and the biological laboratory, respectively.

（2） Types of hazardous waste:

Our company's hazardous waste is mainly generated by various laboratories during the experimental process and in the waste gas treatment equipment, including organic solvents, waste activated carbon, laboratory waste, medical waste, etc.

3、 Production, storage, and disposal of hazardous waste

（1） Hazardous waste generation situation:

1. Organic solvents. The chemical waste liquid generated during the laboratory experiment process is sealed and stored in a special plasticbucket, temporarily stored at a hazardous waste storage point, and promptly transported for treatment.

2. Waste activated carbon: Activated carbon that adsorbs waste gas in the exhaust gas purification box of the laboratory fume hood, is regularly replaced, stored in a hazardous waste storage point for temporary storage, and promptly transported for treatment.

3. Laboratory waste. Solid waste such as empty bottles of experimental chemical reagents and waste labor protection equipment shall be packaged in garbage bags and stored temporarily at hazardous waste storage points for timely transportation and treatment.

4. Medical waste: The corpses of mice during the experimental process are packaged in specialized cardboard boxes and temporarily stored at hazardous waste storage points for timely transportation and treatment.

（2） Hazardous waste storage situation:

Our company has 2 hazardous waste storage points for temporary storage of hazardous waste. Different types of hazardous waste are stored separately in different areas. Hazardous waste warehouses are equipped with obvious hazardous waste warning signs in accordance with national regulations such as the Law of the People's Republic of China on the Prevention and Control of Solid Waste Pollution. Necessary measures such as waterproofing, theft prevention, and leakage prevention have been taken, and security measures such as video surveillance systems have been installed.

Our company entrusts a professional service company to provide on-site services for hazardous waste, with dedicated personnel responsible for the safety management of the collection, weighing, registration, classification and storage processes.

（3） Hazardous waste disposal situation:

The hazardous waste generated by our company is entrusted to Zhangjiagang Huarui Hazardous Waste Treatment Center Co., Ltd. with a business license for harmless treatment.

In 2022, our company disposed of a total of 10.338 tons of hazardous waste.

Previous: World diabetes Day | Benefit diabetes Patients with Source Innovation

Next: New News | CGeneTech was awarded the title of "Independent Innovation Pioneer Enterprise in the Chinese Pharmaceutical Industry"

Previous: World diabetes Day | Benefit diabetes Patients with Source Innovation

Next: New News | CGeneTech was awarded the title of "Independent Innovation Pioneer Enterprise in the Chinese Pharmaceutical Industry"

Milestones | Shengshi Taike's new generation DPP-4 inhibitor approved for market launch

Today, the official website of the National Medical Products Administration (NMPA) of China announced that Shengshi Taike's independently developed Class 1 innovative drug, saxagliptin phosphate tablets (formerly known as saxagliptin phosphate tablets), has been approved for market in China. This is a new generation of highly selective DPP-4 inhibitor, which is suitable for improving the blood sugar control of adult type 2 diabetes patients. According to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China, the prevalence of diabetes among adults in China has risen to 11.2%, of which more than 90% are type 2 diabetes. In order to meet the huge clinical demand, some new drugs with different mechanisms of action from traditional oral hypoglycemic drugs have emerged in recent years. Dipeptidyl peptidase-4 (DPP-4) inhibitors are one of them. They not only improve hyperglycemia, but also are not easy to induce hypoglycemia and weight gain. They have the characteristics of rapid oral absorption, long half-life, and long-lasting effect, and are known as "smart" hypoglycemic drugs. Currently, they have been recommended by many domestic and foreign guidelines. As a new generation of highly selective DPP-4 inhibitor independently developed by Shengshi Taike, sengliptin has been continuously selected for the national "Major New Drug Development" special projects in the 12th and 13th Five Year Plans. Due to the excellent data demonstrated in the first phase clinical trial of the best product in the market, it was exempted from phase 2 clinical trials and directly entered phase 3 clinical trials, pioneering the "exemption from two to three" clinical trials in the field of this drug. The results of the phase III clinical trial of Sengliptin led by Professor Ji Linong, director of the Endocrinology Department of Peking University People's Hospital and director of Peking University diabetes Center, showed that in the single drug treatment trial of Sengliptin, the reduction values of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week were 1.08% and 1.07% respectively; In the treatment trial of sengliptin combined with metformin, the glycated hemoglobin decreased by 1.23% and 1.17% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. Meanwhile, both sets of experimental data showed that patients with higher blood sugar levels experienced a greater decrease in glycated hemoglobin levels. In addition to its excellent hypoglycemic effect, what is even more commendable is that in the comparison between the 100mg dose group (high-dose group) and the placebo group in the last 28 weeks, the incidence of adverse reactions of sengliptin is similar to that of the placebo group, and its safety further solves the common adverse reactions in marketed products. At present, metformin combined with leptin has become the main treatment scheme in the clinical application of treating type 2 diabetes. According to Sullivan's research report, by 2030, the market size of leptin in China will exceed 30 billion, with broad market prospects. Ding Juping, the co-founder and president of Shengshi Tyco, said: "I am very glad to see the company's self-developed product, Sengliptin Phosphate Tablets, has been approved for listing. This drug will be the best new hypoglycemic drug of its kind with half the effort and twice the treatment effect. I hope it will benefit the majority of diabetes patients in China as soon as possible after it is approved for listing." Dr. Yu Qiang, the founder and CEO of Shengshi Tyco, said: "Sengliptin's successful approval for listing benefits from Suzhou and the park as a fertile land for entrepreneurship and the strong support of many departments. It is also a" promise of gold "to use our innovative drugs to repay the business friendly services in Suzhou Park. At this moment, I would like to use an original poem to bless this new drug for its successful launch." Morimu's sounds of nature are listed in the palace. The morning light shines on the clouds, and the prosperous world welcomes the sunrise.

2024-12-05